Loading candles…
Kilitch Drugs Ltd, incorporated in 1978, operates in the pharmaceutical industry, focusing on the development, manufacture, and marketing of a diverse range of pharmaceutical formulations. The company produces various dosage forms including injectables, ophthalmics, and solid orals. It combines contract manufacturing services with efforts to establish its own brand portfolio. Kilitch Drugs Ltd serves both domestic and international markets, with particular emphasis on emerging markets such as Africa. Recognized as a key player in contract manufacturing, the company maintains a presence across multiple geographies without listed subsidiaries or public exchange listings.
This page is a live market overview for KILITCH DRUGS INDIA LTD (KILITCH) on the NSE. As a listed security, KILITCH DRUGS INDIA LTD is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for KILITCH before placing trades on tick2trade.
As of the latest feed, KILITCH last traded at ₹217.23 on NSE, up ₹0 (0.00%) from the previous close of ₹217.23. Today's session range is ₹0 – ₹0, against a 52-week band of ₹117.25 – ₹232.5. Traded volume today stands at 85.94K shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for KILITCH in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether KILITCH is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for KILITCH DRUGS INDIA LTD before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in KILITCH. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated KILITCH option chain page linked from this overview.
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 13 Aug 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 | 15 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025, Bonus Issue, Increase Authorised Capital, Convene EGM, finalise the rec… | 11 Feb 2026 |
| Other | to consider increase in authorised capital, to convene EGM, to finalise record date | 11 Feb 2026 |
| Bonus | To consider bonus issue | 11 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 13 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 13 Aug 2025 |
| Fund Raising | To consider Fund Raising | 2 Jul 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.